EP3367386 - PATIENT CUSTOMIZED THERAPEUTIC REGIMENS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 04.03.2021 Database last updated on 03.09.2024 | |
Former | Request for examination was made Status updated on 08.03.2019 | ||
Former | The application has been published Status updated on 27.07.2018 | Most recent event Tooltip | 09.07.2024 | New entry: Date of oral proceedings | Applicant(s) | For all designated states Otsuka Pharmaceutical Co., Ltd. 2-9, Kanda Tsukasa-machi Chiyoda-ku Tokyo 101-8535 / JP | [2021/21] |
Former [2018/35] | For all designated states Proteus Digital Health, Inc. 2600 Bridge Parkway, Suite 101 Redwood City, CA 94065 / US | Inventor(s) | 01 /
ZDEBLICK, Mark 300 La Mesa Drive Portola Valley California, CA 94028 / US | 02 /
THOMPSON, Andrew 840 Westridge Drive Portola Valley California, CA 94028 / US | 03 /
SAVAGE, George 1180 Westridge Drive Portola Valley California, CA 94028 / US | [2018/35] | Representative(s) | Murgitroyd & Company 165-169 Scotland Street Glasgow G5 8PL / GB | [N/P] |
Former [2018/35] | Murgitroyd & Company Scotland House 165-169 Scotland Street Glasgow G5 8PL / GB | Application number, filing date | 18167390.6 | 02.05.2007 | [2018/35] | Priority number, date | US20060746250P | 02.05.2006 Original published format: US 746250 P | [2018/35] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3367386 | Date: | 29.08.2018 | Language: | EN | [2018/35] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 31.07.2018 | Classification | IPC: | G16H20/10 | [2018/35] | CPC: |
G06Q10/00 (EP,US);
G16H50/20 (KR,US);
A61B5/0002 (EP,KR,US);
A61B5/0028 (KR,US);
A61B5/073 (EP,KR,US);
A61B5/4833 (EP,KR,US);
A61B5/4848 (KR,US);
G16H10/60 (KR);
G16H20/10 (EP,KR,US);
G16H40/67 (EP,US);
H01M8/02 (US);
H04B13/005 (EP,KR,US);
H01M2220/10 (US);
Y02E60/10 (EP);
Y02E60/50 (EP);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR [2019/15] |
Former [2018/35] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR | Title | German: | PATIENTENSPEZIFISCHE THERAPIEFORMEN | [2018/35] | English: | PATIENT CUSTOMIZED THERAPEUTIC REGIMENS | [2018/35] | French: | RÉGIMES THÉRAPEUTIQUES PERSONNALISÉS DE PATIENTS | [2018/35] | Examination procedure | 28.02.2019 | Amendment by applicant (claims and/or description) | 28.02.2019 | Examination requested [2019/15] | 28.02.2019 | Date on which the examining division has become responsible | 03.03.2021 | Despatch of a communication from the examining division (Time limit: M04) | 06.07.2021 | Reply to a communication from the examining division | 02.07.2024 | Cancellation of oral proceeding that was planned for 12.11.2024 | 12.11.2024 | Date of oral proceedings (cancelled) | 29.11.2024 | Date of oral proceedings | Parent application(s) Tooltip | EP07776655.8 / EP2013829 | Fees paid | Renewal fee | 13.04.2018 | Renewal fee patent year 03 | 13.04.2018 | Renewal fee patent year 04 | 13.04.2018 | Renewal fee patent year 05 | 13.04.2018 | Renewal fee patent year 06 | 13.04.2018 | Renewal fee patent year 07 | 13.04.2018 | Renewal fee patent year 08 | 13.04.2018 | Renewal fee patent year 09 | 13.04.2018 | Renewal fee patent year 10 | 13.04.2018 | Renewal fee patent year 11 | 13.04.2018 | Renewal fee patent year 12 | 30.05.2019 | Renewal fee patent year 13 | 30.03.2020 | Renewal fee patent year 14 | 21.05.2021 | Renewal fee patent year 15 | 26.05.2022 | Renewal fee patent year 16 | 31.05.2023 | Renewal fee patent year 17 | 29.05.2024 | Renewal fee patent year 18 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]US5079006 (URQUHART JOHN [US]); | [X]US2002032385 (RAYMOND STEPHEN A [US], et al); | [A]US2004193446 (MAYER STEVEN LLOYD [US], et al); | [A]US2005187789 (HATLESTAD JOHN [US], et al); | [XP]WO2006116718 (PROTEUS BIOMEDICAL INC [US], et al) | by applicant | US4360125 | US4768176 | US4768177 | US5079006 | US5200891 | US5642731 | US5752235 | US5954641 | WO0147466 | US2004193021 | WO2005020023 | US2006058588 | WO2006055892 | WO2006104843 | WO2006116718 | WO2006127355 | WO2007001742 | WO2007001724 | WO2007014084 | WO2007013952 | WO2007021496 | WO2007027660 | WO2007028035 | EP2013829 | US20040764429 | US20040764127 | US20040764125 | WO2004US41430 | US20050249152 | WO2005US39535 | WO2005US46815 | US20050324196 | US20060368259 | US20060819750 | US20060829832 | US20060866581 | US20070887780 | US20070889868 | US20070889870 | US20070889871 | US20070891883 | US20070894171 | US20070894167 |